IP Library Granted Patent US 8,580,974
Granted Patent B2
US 8,580,974 · App. 12/863,213 · Granted Nov 12, 2013

Processes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,580,974
App. No.
12/863,213
Granted
Nov 12, 2013
Kind
B2
Abstract

The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-δ-biphenyl-α-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.

Claims (20)

1. A compound of formula (4)

or a salt thereof,

wherein R1 is hydrogen or a nitrogen protecting group, having a configuration according to formula (4-a),

2. A compound of formula (5), or a salt thereof,

wherein R1 is hydrogen or a nitrogen protecting group, of formulae (5-a), (5-b) or (5-c),

3. A compound of formula (6), or a tautomer thereof,

or a salt thereof,

wherein R1 is hydrogen or a nitrogen protecting group, having a configuration according to formula (6-a),

4. A compound of formula (7), or a salt thereof,

wherein R1 is hydrogen or a nitrogen protecting group and, R6 and R7 are, independently, an alkyl group, an aryl group, an arylalkyl group, a cycloalkyl group or together R6 and R7 form a cycle, together with the nitrogen to which they are attached, which cycle may be saturated or unsaturated and may optionally contain one or more heteroatoms, including nitrogen, oxygen or sulphur, whereby the cycle contains 3 to 8, ring atoms, having a configuration according to formula (7-a), (7-b) or (7-c),

5. A compound of formula (9-a), or a salt thereof,

wherein R1 is hydrogen or a nitrogen protecting group and, R6 and R7 are, independently, an alkyl group or together are an alkylene group, having a configuration according to formula (9-a) (9-b) or (9-c),

6. A compound of formula (10), or a salt thereof,

wherein R1 is hydrogen or a nitrogen protecting group, R6 and R7 are, independently, an alkyl group, an aryl group, an arylalkyl group, a cycloalkyl group or together R6 and R7 form a cycle, together with the nitrogen to which they are attached, which cycle may be saturated or unsaturated and may optionally contain one or more heteroatoms, including nitrogen, oxygen or sulphur, whereby the cycle contains 3 to 8, ring atoms, Z − is a halide, an alkyl sulphate or a sulfonyl ester and R10 is hydrogen, alkyl or aryl; having a configuration according to formula (10-a), (10-b) or (10-c),

7. A compound of formula (11)

or a salt thereof, wherein R1 is hydrogen or a nitrogen protecting group and R4 is an OH-activating group, having a configuration according to formula (11-a), (11-b) or (11-c),

8. A compound of formula (16)

or a salt thereof,

wherein R1 is hydrogen or a nitrogen protecting group, Y is O or S and each R9, is, independently, alkyl, aryl, arylalkyl or acetyl

having a configuration according to formula (16-a),

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2011
From: NOVARTIS AG
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 026002/0790 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2010
From: HOOK, DAVID; RISS, BERNHARD; KAUFMANN, DANIEL; NAPP, MATTHIAS; BAPPERT, ERHARD; POLLEUX, PHILIPPE; MEDLOCK, JONATHAN; ZANOTTI-GEROSA, ANTONIO
To: NOVARTIS AG
Reel/Frame 025030/0476 →